Fused bicyclic kinase inhibitors

US8445510B2 · kind B2 · utility

Assignee

• OSI Pharmaceuticals, LLC · US

Inventors

• Mark J. Mulvihill · Melville, US
• Arno G. Steinig · East Northport, US
• Andrew Philip Crew · North Babylon, US
• Meizhong Jin · Dix Hills, US
• Andrew Kleinberg · Roslyn Heights, US
• An-Hu Li · New York, US
• Jing Wang · Acton, US

Key dates

• Filing date: May 16, 2011
• Grant date: May 21, 2013
• Expiry date: May 16, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula I, as shown below and defined herein:pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.